Pembrolizumab-related hand and foot skin reaction.

Authors

Francesca Ambrogio, Carmelo Laface, Cosimo Castronovi, Riccardo Bortone, Edoardo Mortato, Fortunato Cassalia, Gerardo Cazzato, Caterina Foti

Published in

Dermatology reports. Oct 05, 2026. Epub Oct 05, 2026.

Abstract

Hand and foot skin reaction (HFSR), usually associated with tyrosine kinase inhibitors, is characterized by painful erythema and hyperkeratosis at palmoplantar pressure points. HFSR differs from the more widely recognized chemotherapy-induced hand-foot syndrome (HFS) in terms of both clinical and histopathological features. Here we present the case of a 79-year-old man with advanced lung adenocarcinoma who developed grade 3 HFSR after receiving pembrolizumab, a PD-1 inhibitor. The patient initially presented with erythema, desquamation, and hyperkeratotic plaques on the palms and soles, followed by the development of vesiculobullous lesions. Histopathological findings supported the clinical diagnosis. Treatment included discontinuation of pembrolizumab, along with systemic and topical corticosteroids and salicylic acid, with marked improvement and resolution after about 2 months. Given the impact on quality of life and treatment continuity, clinicians should monitor for HFSR in patients receiving immune checkpoint inhibitors (ICIs) to allow for timely intervention.

PMID:
42831863
Bibliographic data and abstract were imported from PubMed on 05 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.